Loic Ysebaert, MD
IUCT Oncopole de Toulouse
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Loic Ysebaert, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:52 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT02889523 · Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by ChemiotherapyThe Lymphoma Academic Research Organisation · active not recruiting · Lymphoma, DLBCL, Follicular Lymphoma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:52 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:52 UTC. The ranking covers the 200 most relevant of 16 PubMed records, and a shared surname and initials can bring in a namesake. All 16 on PubMed
- 105 citationsRCR 5.1
- Hybrid Closed-Loop Control Is Safe and Effective for People with Type 1 Diabetes Who Are at Moderate to High Risk for Hypoglycemia.Diabetes Technol Ther · 201954 citationsRCR 2.7
- 45 citationsRCR 2.0
- 45 citationsRCR 1.5
- Perceptual versus conceptual interference and pattern separation of verbal stimuli in young and older adults.Hippocampus · 201341 citationsRCR 1.7
- Evaluation of cutaneous immune response in a controlled human in vivo model of mosquito bites.Nat Commun · 202236 citationsRCR 2.7
- Development and initial validation of the Asthma Severity Scoring System (ASSESS).J Allergy Clin Immunol · 202028 citationsRCR 1.5
- Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma.Radiother Oncol · 201927 citationsRCR 1.1
- 23 citationsRCR 1.3
- Composition of plaque and saliva following use of an alpha-tricalcium-phosphate-containing chewing gum and a subsequent sucrose challenge.J Dent Res · 200022 citationsRCR 1.2